Assessment of Homologous Recombination Deficiency in Ovarian Cancer

A novel split PEC sensor based on magneto-optic nanostructure and photocurrent polarity switching strategy

BACKGROUND

Photoelectrochemical (PEC) sensors have attracted much attention due to their low cost, simple instrumentation and high sensitivity. However, conventional PEC sensors require layer-by-layer modification of the photoelectrode surface, which has the disadvantages of being time-consuming and unstable. In addition, complex interfering substances in real samples may lead to false-positive or false-negative detection results. It was thought that the above drawbacks could be eliminated by the construction of a polarity inversion PEC sensor. In this work, a magnetically separated PEC sensor was constructed for the detection of Carcinoembryonic antigen (CEA).

RESULTS

During the experiment, the construction of the sensor was used for sensitive detection of CEA. In the experimental process, Fe3O4@SiO2@CdS, a semiconductor material with magnetic properties, was chosen as the substrate material, and ZnO/CuO was used as the marker on the DNA2 molecule, and a split magnetic separation PEC sensor was constructed, which was used to realize the sensitive detection of CEA. Eventually, the detection range of the sensor for CEA detection is 1-10000 pg/mL, with the detection limit of 0.34 pg/mL. Additionally, the PEC sensor has the advantages of high speed, high efficiency, high sensitivity, good specificity, and high stability. The sensing platform constructed in this work can also be extended to detect other targets, which provides a new idea for PEC sensing platforms.

SIGNIFICANCE

In this experiment, we developed a split PEC immunosensor based on magneto-optic nanostructure and photocurrent polarity switching strategy. Specifically, the proposed magnetic nanostructure Fe3O4@SiO2@CdS-DNA1 exhibits good paramagnetism and dispersion ability. By magnetic separation process, the PEC signals of opposite polarity can be obtained.

Evaluation of Homologous Recombination Deficiency in Ovarian Cancer

OPINION STATEMENT

Homologous recombination deficiency (HRD) is an important biomarker guiding selection of ovarian cancer patients who will derive the most benefit from poly(ADP-ribose) polymerase inhibitors (PARPi). HRD prevents cells from repairing double-stranded DNA damage with high fidelity, PARPis limit single-stranded repair, and together these deficits induce synthetic lethality. Germline or somatic BRCA mutations represent the narrowest definition of HRD, but do not reflect all patients who will have a durable PARPi response. HRD can also be defined by its downstream consequences, which are measured by different metrics depending on the test used. Ideally, all patients will undergo genetic counseling and germline testing shortly after diagnosis and have somatic testing sent once an adequate tumor sample is available. Should barriers to one test be higher, pursuing germline testing with reflex to somatic testing for BRCA wildtype patients or somatic testing first strategies are both evidence-based. Ultimately both tests offer complementary information, germline testing should be pursued for any patient with a history of ovarian cancer, and somatic testing is valuable at recurrence if not performed in the upfront setting. There is a paucity of data to suggest superiority of one germline or somatic assay; therefore, selection should optimize turnaround time, cost to patients, preferred result format, and logistical burden. Each clinic should implement a standard testing strategy for all ovarian cancer patients that ensures HRD status is known at the time of upfront chemotherapy completion to facilitate comprehensive counseling about anticipated maintenance PARPi benefit.

Metronomic chemotherapy in ovarian cancer

Translational research and the development of targeted therapies have transformed the therapeutic landscape in epithelial ovarian cancer over the last decade. However, recurrent ovarian cancer continues to pose formidable challenges to therapeutic interventions, necessitating innovative strategies to optimize treatment outcomes. Current research focuses on the development of pharmaceuticals that target potential resistance pathways to DNA repair pathways. However, the cost and toxicity of some of these therapies are prohibitive and majority of patients lack access to clinical trials. Metronomic chemotherapy, characterized by the continuous administration of low doses of chemotherapeutic agents without long treatment breaks, has emerged as a promising approach with potential implications beyond recurrent setting. It acts primarily by inhibition of angiogenesis and activation of host immune system. We here review the mechanism of action of metronomic chemotherapy, as well as its current role, limitations, and avenues for further research in the management of epithelial ovarian cancer.